Mental Depression disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MNT002 MIFTS: 51	Mental Depression Categories: Mental diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression ¹¹ ⁵ ¹⁴ ⁷¹

Depressive Disorder ⁷¹

Depression ⁴³

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Mental and behavioural disorders

Mood [affective] disorders

Recurrent depressive disorder

Recurrent depressive disorder, unspecified

External Ids:

Disease Ontology ¹¹ DOID:1596

MeSH ⁴³ D003863

NCIt ⁴⁹ C2982

SNOMED-CT ⁶⁸ 41006004

ICD10 ³¹ F33.9

UMLS ⁷¹ C0011570 C0011581

Sources

Summaries for Mental Depression

MalaCards based summary: Mental Depression, also known as depressive disorder, is related to postpartum depression and bipolar disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Signal Transduction and Interleukin-4 and Interleukin-13 signaling. The drugs Propofol and Trimipramine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and breast, and related phenotypes are nervous system and behavior/neurological

Sources

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2476)

#	Related Disease	Score	Top Affiliating Genes
1	postpartum depression	33.2	SLC6A4 POMC OXT MAOA IL6 HTR2A
2	bipolar disorder	33.1	SLC6A4 PRODH MIR132 MAOA IL6 HTR2A
3	anxiety	32.8	SLC6A4 PRODH POMC OXT MAOA IL6
4	atypical depressive disorder	32.7	SLC6A4 SERPINA3 POMC MAOA IL6 HTR2A
5	dysthymic disorder	32.5	SLC6A4 PRODH POMC OXT MAOA IL6
6	major depressive disorder	32.4	TWNK SLC6A4 POMC OXT NOTCH3 MAOA
7	headache	32.4	SLC6A4 HTR2A BDNF
8	bipolar i disorder	32.3	SLC6A4 PRODH HTR2A HTR1A BDNF
9	alcohol use disorder	32.3	SLC6A4 SERPINA3 PRODH POMC MAOA IL6
10	fibromyalgia	32.3	SLC6A4 POMC OXT MAOA IL6 HTR2A
11	eating disorder	32.3	SLC6A4 POMC OXT HTR2A HTR1A H2AC18
12	schizoaffective disorder	32.3	SLC6A4 SERPINA3 PRODH HTR2A HTR1A BDNF
13	dementia	32.3	SERPINA3 NOTCH3 MAOA IL6 HTR2A HTR1A
14	personality disorder	32.2	SLC6A4 MAOA HTR2A HTR1A CRH BDNF
15	parkinson disease, late-onset	32.2	SLC6A4 SERPINA3 PRODH MIRLET7D MIR132 MIR124-1
16	dementia, lewy body	32.2	SERPINA3 MIRLET7D MIR132 H2AC18 BDNF
17	sleep apnea	32.2	SLC6A4 IL6 HTR2A BDNF
18	bulimia nervosa	32.1	SLC6A4 OXT MAOA HTR2A BDNF
19	borderline personality disorder	32.1	SLC6A4 MAOA HTR2A HTR1A CRH BDNF
20	gilles de la tourette syndrome	32.1	SLC6A4 MAOA HTR2A HTR1A BDNF
21	apnea, obstructive sleep	32.1	POMC MIRLET7D IL6 HTR2A BDNF
22	migraine with or without aura 1	32.1	SLC6A4 SERPINA3 POMC OXT NOTCH3 MAOA
23	supranuclear palsy, progressive, 1	32.0	SERPINA3 MIR132 DCTN1
24	obsessive-compulsive disorder	32.0	SLC6A4 POMC OXT MAOA IL6 HTR2A
25	cyclothymic disorder	32.0	SLC6A4 HTR2A HTR1A BDNF
26	post-traumatic stress disorder	32.0	SLC6A4 POMC OXT MIR124-1 MAOA IL6
27	huntington disease	32.0	SERPINA3 PRODH MIR132 MAOA H2AC18 BDNF
28	type 2 diabetes mellitus	32.0	SERPINA3 PRODH POMC MIRLET7D IL6 HTR2A
29	schizophrenia	32.0	SLC6A4 SERPINA3 PRODH POMC OXT MIR132
30	interstitial cystitis	32.0	IL6 CRH BDNF
31	autism spectrum disorder	32.0	SLC6A4 PRODH OXT MIR598 MIR132 MAOA
32	panic disorder	32.0	SLC6A4 POMC MAOA IL6 HTR2A HTR1A
33	stroke, ischemic	31.9	SERPINA3 NOTCH3 MIR124-1 IL6 BDNF
34	acne	31.9	POMC IL6 CRH
35	cerebrovascular disease	31.9	SERPINA3 NOTCH3 MIR132 MIR124-1 IL6 H2AC18
36	endogenous depression	31.9	SLC6A4 POMC OXT MAOA IL6 HTR2A
37	binswanger's disease	31.9	NOTCH3 CRH
38	acute stress disorder	31.9	SLC6A4 POMC OXT HTR2A CRH BDNF
39	generalized anxiety disorder	31.9	SLC6A4 PRODH POMC OXT MAOA IL6
40	adult syndrome	31.8	POMC IL6 H2AC18 CRH
41	alcohol dependence	31.8	SLC6A4 SERPINA3 POMC MAOA HTR2A HTR1A
42	conversion disorder	31.8	HTR2A BDNF
43	pulmonary disease, chronic obstructive	31.8	SERPINA3 MIRLET7D IL6 H2AC18
44	mild cognitive impairment	31.8	SERPINA3 MIRLET7D MIR132 IL6 BDNF
45	psychotic disorder	31.8	SLC6A4 SERPINA3 PRODH OXT MIRLET7D MIR598
46	diabetes mellitus	31.7	SERPINA3 POMC OXT MIR132 IL6 CRH
47	epilepsy	31.7	PRODH POMC MIR132 MIR124-1 MAOA IL6
48	melancholia	31.7	SLC6A4 POMC OXT MAOA IL6 HTR2A
49	asperger syndrome	31.7	SLC6A4 OXT BDNF
50	alexithymia	31.7	SLC6A4 OXT HTR2A H2AC18 CRH BDNF

Graphical network of the top 20 diseases related to Mental Depression:

Sources

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:

dejection emotional; depressed reaction; depression aggravated; affective symptoms; behavioral symptoms; schizophrenic language; depressive symptoms; depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.77	BDNF CRH DCTN1 HTR1A IL6 MAOA
2	behavior/neurological	MP:0005386	9.5	BDNF CRH DCTN1 HTR1A HTR2A IL6

Sources

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 768)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Trimipramine

Approved

Phase 4

739-71-9

5584

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Copper

Approved, Investigational

Phase 4

7440-50-8

27099

Norethisterone

Approved

Phase 4

68-22-4

199472 6230

Lactulose

Approved

Phase 4

4618-18-2

11333

Bromocriptine

Approved, Investigational, Withdrawn

Phase 4

25614-03-3

31101

Atomoxetine

Approved

Phase 4

82248-59-7, 83015-26-3

54841

Isocarboxazid

Approved

Phase 4

59-63-2

3759

Protriptyline

Approved

Phase 4

438-60-8

4976

Desipramine

Approved, Investigational

Phase 4

50-47-5

2995

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Rasagiline

Approved

Phase 4

136236-51-6

3052776

Ribavirin

Approved

Phase 4

36791-04-5

37542

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Cycloserine

Approved

Phase 4

68-41-7

6234

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Esomeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6, 119141-88-7

9568614 4594

Eszopiclone

Approved, Investigational

Phase 4

138729-47-2

969472

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Nefazodone

Approved, Withdrawn

Phase 4

82752-99-6, 83366-66-9

4449

Haloperidol

Approved

Phase 4

52-86-8

3559

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Ropinirole

Approved, Investigational

Phase 4

91374-21-9

5095

Iloperidone

Approved

Phase 4

133454-47-4

71360

Losartan

Approved

Phase 4

114798-26-4

3961

Exenatide

Approved, Investigational

Phase 4

141758-74-9

45588096

Zolpidem

Approved

Phase 4

82626-48-0

5732

Raloxifene

Approved, Investigational

Phase 4

82640-04-8, 84449-90-1

5035

Alendronic acid

Approved

Phase 4

121268-17-5, 66376-36-1

2088

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Bazedoxifene

Approved, Investigational

Phase 4

198481-32-2

154257

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Leuprolide

Approved, Investigational

Phase 4

53714-56-0

657181

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

Benzatropine

Approved

Phase 4

86-13-5

1201549

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Doxylamine

Approved, Vet_approved

Phase 4

562-10-7, 469-21-6

3162

Rilpivirine

Approved

Phase 4

500287-72-9

6451164

Racivir

Approved, Investigational

Phase 4

143491-57-0, 143491-54-7

60877

Rotigotine

Approved

Phase 4

99755-59-6, 92206-54-7

57537 59227

gamma-Aminobutyric acid

Approved, Investigational

Phase 4

56-12-2

119

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Coal tar

Approved

Phase 4

8007-45-2

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Interventional clinical trials:

(show top 50) (show all 7988)

#	Name	Status	NCT ID	Phase	Drugs
1	Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder	Unknown status	NCT02752542	Phase 4	Pharmacotherapy
2	International Study to Predict Optimised Treatment - in Depression	Unknown status	NCT00693849	Phase 4	Escitalopram;Sertraline;Venlafaxine-XR
3	Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder	Unknown status	NCT01699490	Phase 4	Fluoxetine + Valsartan;Fluoxetine + Placebo
4	Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label	Unknown status	NCT00650897	Phase 4	Escitalopram
5	D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression	Unknown status	NCT02772211	Phase 4	Ketamine;D-cycloserine;Placebo
6	Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)	Unknown status	NCT02711215	Phase 4	Citalopram;Escitalopram (Mirtazapine/Duloxetine/Venlafaxine);Placebo
7	A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia	Unknown status	NCT02669030	Phase 4	suvorexant;Placebo
8	Clinical Trial of the Use of Ketamine in Treatment Resistant Depression	Unknown status	NCT02610712	Phase 4	Ketamine
9	Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder	Unknown status	NCT02294305	Phase 4	Vortioxetine;Placebo
10	Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder	Unknown status	NCT00442481	Phase 4	Escitalopram
11	Ketamine Enhancement of rTMS for Refractory Depression	Unknown status	NCT04352621	Phase 4	intranasal ketamine
12	Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder	Unknown status	NCT01997580	Phase 4	escitalopram
13	A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole	Unknown status	NCT03881449	Phase 4
14	Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder	Unknown status	NCT02273154	Phase 4	Buspirone;Paroxetine
15	A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder	Unknown status	NCT04138290	Phase 4
16	THE AIUNI - Integral Assessment in Unipolar Depression	Unknown status	NCT02268487	Phase 4	Sertraline
17	Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy	Unknown status	NCT03187093	Phase 4	Vortioxetine;Escitalopram
18	Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis	Unknown status	NCT02330679	Phase 4	Desvenlafaxine;Placebo
19	Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics	Unknown status	NCT03219008	Phase 4	Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
20	Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder	Unknown status	NCT02346682	Phase 4	venlafaxine
21	Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial	Unknown status	NCT03666494	Phase 4	Ketamine Hydrochloride;Propofol;Fentanyl
22	Brain Mechanisms and Targeting Insomnia in Major Depression	Unknown status	NCT00628914	Phase 4	escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
23	A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression.	Unknown status	NCT00335205	Phase 4	ropinirole
24	Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression	Unknown status	NCT00291239	Phase 4
25	Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial	Unknown status	NCT00209807	Phase 4	escitalopram;Reboxetine
26	The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders	Unknown status	NCT03122158	Phase 4	Escitalopram
27	Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life	Unknown status	NCT00889369	Phase 4	Duloxetine
28	Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart	Unknown status	NCT01568307	Phase 4	Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
29	A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder.	Unknown status	NCT01483053	Phase 4	Agomelatine;Escitalopram
30	Algorithm Guided Treatment Strategies for Major Depressive Disorder	Unknown status	NCT01764867	Phase 4	Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Bupropion;Trazodone
31	Pharmacogenomics Studies of Antidepressants	Unknown status	NCT01204086	Phase 4	Venlafaxine;Fluoxetine
32	The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope	Unknown status	NCT01357967	Phase 4	SSRI monotherapy;Seroquel XR adjunctive
33	Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study	Unknown status	NCT01391221	Phase 4	Duloxetine
34	White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study	Unknown status	NCT01492621	Phase 4	Desvenlafaxine
35	Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder	Unknown status	NCT01460212	Phase 4	SSRI antidepressants
36	Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2	Unknown status	NCT00519012	Phase 4	Sertraline to Paroxetine;Paroxetine to Sertraline
37	A Prospective, Single-Blinded, Randomized, Multicentre Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Subjects With a Primary Diagnosis of a Depressive Disorder	Unknown status	NCT04620499	Phase 4
38	Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial	Unknown status	NCT04589143	Phase 4	Agomelatine;Placebos
39	A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD)	Unknown status	NCT01556971	Phase 4	Botox;Saline Solution
40	Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder	Unknown status	NCT02213016	Phase 4
41	Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder	Unknown status	NCT02924090	Phase 4	Etomidate;Ketamine
42	Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression	Unknown status	NCT04234776	Phase 4	Ketamine
43	Turgut Ozal Medical Center Department of Anesthesiology and Reanimation	Unknown status	NCT02267980	Phase 4	Sevoflurane;Ketamine;Saline
44	Objective to Evaluate the Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Depressive Episode: a Multicenter Open Randomized Controlled Clinical Trial	Unknown status	NCT04826510	Phase 4	Perospirone hydrochloride tablets;Lithium carbonate + perospirone hydrochloride;Lithium Carbonate Pill
45	Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.	Unknown status	NCT03491696	Phase 4	Metyrapone
46	Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child	Unknown status	NCT01796132	Phase 4	SSRI/SNRI
47	The Assessment of Osteoporosis Treatment in Post-menopausal Women	Unknown status	NCT03006003	Phase 4	Raloxifene;Alendronate
48	Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression	Unknown status	NCT03328052	Phase 4
49	A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression	Unknown status	NCT01974934	Phase 4	Desvenlafaxine Succinate
50	A Comparative Trial of TMS Approaches to Treating Depression	Unknown status	NCT01906905	Phase 4

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Alprazolam

Amitriptyline

Amitriptyline Hydrochloride

Amoxapine

Bupropion

Bupropion hydrobromide

Bupropion Hydrochloride

Buspirone

buspirone hydrochloride

Citalopram

Citalopram hydrobromide

Clomipramine

Clomipramine Hydrochloride

Desipramine

Desipramine Hydrochloride

Doxepin

Doxepin Hydrochloride

Escitalopram

Escitalopram oxalate

Fluoxetine

Fluoxetine Hydrochloride

Fluvoxamine

Fluvoxamine Maleate

HYPERICUM PERFORATUM (ST. JOHN'S WORT)

Imipramine

Imipramine Hydrochloride

Imipramine pamoate

Isocarboxazid

Isoflurane

Kava preparation

Lithium

Lithium Aspartate

Lithium Carbonate

lithium citrate

Lorazepam

Maprotiline

Maprotiline Hydrochloride

Methylphenidate

Methylphenidate Hydrochloride

Mirtazapine

nefazodone

Nortriptyline

Nortriptyline Hydrochloride

Paroxetine

Paroxetine Hydrochloride

Phenelzine

Phenelzine Sulfate

Pramipexole

Pramipexole dihydrochloride

Protriptyline

Protriptyline Hydrochloride

Selegiline

selegiline hydrochloride

Sertraline

Sertraline Hydrochloride

Temazepam

Tranylcypromine

Tranylcypromine sulfate

Trazodone

Trazodone Hydrochloride

Tricyclic Antidepressant [EPC]

Trimipramine

Trimipramine Maleate

venlafaxine

Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Sources

Genetic Tests for Mental Depression

Sources

Anatomical Context for Mental Depression

Organs/tissues related to Mental Depression:

MalaCards : Brain, Prefrontal Cortex, Breast, Heart, Temporal Lobe, Spinal Cord, Cortex

Sources

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 307)

#	Title	Authors	PMID	Year
1	Whole-genome sequencing of patients with rare diseases in a national health system. ⁵	Turro E...Ouwehand WH	32581362	2020
2	Loss of Nardilysin, a Mitochondrial Co-chaperone for α-Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration. ⁵	Yoon WH...Bellen HJ	28017472	2017
3	A network pharmacology approach to predict potential targets and mechanisms of "Ramulus Cinnamomi (cassiae) - Paeonia lactiflora" herb pair in the treatment of chronic pain with comorbid anxiety and depression. ⁶²	Pan HT...Wang K	35098831	2022
4	Exercise facilitates regeneration after severe nerve transection and further modulates neural plasticity. ⁶²	Kong Y...Duan B	36405423	2022
5	The Structural Relationship on Nostalgia Recognition Effect, Attachment, Resilience, and Psychological Well-Being of Dance for All Participants during the COVID-19 Pandemic. ⁶²	Lim SY...Kim YH	36141405	2022
6	Berberine: is a Promising Agent for Mental Disorders Treatment? ⁶²	Shayganfard M	35538795	2022
7	[Establishment and comparison of three human multiple myeloma cell line transplantation models in mice]. ⁶²	Liu LT...Hao M	35680600	2022
8	Influence of dental magnets on human brain activity: A quantitative EEG analysis. ⁶²	Elias A...Thallam Veeravalli P	34553779	2022
9	Outcomes of upper gastrointestinal cancer screening in high-risk individuals: a population-based prospective study in Northeast China. ⁶²	Yu Z...Liu Y	35168959	2022
10	Herbal Approaches in the Management of Mental Depression. ⁶²	Garg P...Garg V	35088681	2022
11	Analysis and Research on the Rehabilitation Effect of Physical Exercise on College Students' Mental Depression Based on Multidimensional Data Mining. ⁶²	Zou W	35912309	2022
12	Empirical Investigation for Predicting Depression from Different Machine Learning Based Voice Recognition Techniques. ⁶²	Punithavathi R...Mamo SA	35432567	2022
13	A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment. ⁶²	Sahu K...Singh A	35240956	2022
14	Dezocine Has the Potential to Regulate the Clinical and Biological Features of Tumors. ⁶²	Hu X...Hu P	35478934	2022
15	Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review). ⁶²	Abdel-Bakky MS...Abdellatif AAH	34633054	2021
16	The Relationship Between Neighborhood Deprivation and Perceived Changes for Pain-Related Experiences Among US Patients with Chronic Low Back Pain During the COVID-19 Pandemic. ⁶²	Rassu FS...Skolasky RL	34181008	2021
17	Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-onset Diabetes. ⁶²	Park JI...Cho EH	34227263	2021
18	The burden of mental disorders in Mexico, 1990-2019: Mental and neurological disorders, substance use, suicides, and related somatic disorders. ⁶²	Garcia-Pacheco JA...Borges G	34246817	2021
19	Neural Network Based Mental Depression Identification and Sentiments Classification Technique From Speech Signals: A COVID-19 Focused Pandemic Study. ⁶²	Ahmed ST...Aboudaif MK	34938711	2021
20	Anxiety, Anger and Depression Amongst Low-Income Earners in Southwestern Uganda During the COVID-19 Total Lockdown. ⁶²	Archibong V...Welburn SC	34956994	2021
21	Antidepressant Mechanism of Traditional Chinese Medicine Formula Xiaoyaosan in CUMS-Induced Depressed Mouse Model via RIPK1-RIPK3-MLKL Mediated Necroptosis Based on Network Pharmacology Analysis. ⁶²	Yan ZY...Chen JX	34867405	2021
22	The importance of and satisfaction with sex life among breast cancer survivors in comparison with healthy female controls and women with mental depression or arterial hypertension: results from the Finnish nationwide HeSSup cohort study. ⁶²	Salakari M...Suominen S	31836939	2020
23	Ethnopharmacology of Hypericum species in China: A comprehensive review on ethnobotany, phytochemistry and pharmacology. ⁶²	Zhang R...Long C	32101776	2020
24	Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series. ⁶²	Dirar QS...Almalki AA	32251268	2020
25	Effect of antidepressants on various periodontal parameters: A case-control study. ⁶²	Bey A...Ahmed S	32189839	2020
26	Overview of dropped head syndrome (Combined survey report of three facilities). ⁶²	Endo K...Yamamoto K	31444010	2019
27	[Exploration of modern scientific connotation of Miao medicine Qizu Xueyu syndrome and intervention mechanism of Kangfuyan Capsules]. ⁶²	Chen HG...Zhou X	31872611	2019
28	Recovery of chicken growth plate by TanshinoneⅡA through wnt/β-catenin pathway in thiram-induced Tibial Dyschondroplasia. ⁶²	Yang H...Shen Y	31442808	2019
29	Fecal microbiota transplantation in an elderly patient with mental depression. ⁶²	Cai T...Wang F	30782238	2019
30	Persistent pit viper envenomation in three dogs. ⁶²	Schaer M	31129161	2019
31	The Effect of Interventional Pain Management on Treating Postherpetic Neuralgia. ⁶²	Guo S...Wang G	31148876	2019
32	Aesthetic abdominoplasty has a positive impact on quality of life prospectively. ⁶²	Papadopulos NA...Kloppel M	30638894	2019
33	Stress and perceived social isolation (loneliness). ⁶²	Campagne DM	30825769	2019
34	The Mental Health of Young Canadians Who Are Not Working or in School. ⁶²	Gariepy G...Iyer S	30595044	2019
35	Overexpression of microRNA-301b accelerates hippocampal microglia activation and cognitive impairment in mice with depressive-like behavior through the NF-κB signaling pathway. ⁶²	Tang CZ...Wang WS	30962417	2019
36	The emergence of a highly pathogenic porcine reproductive and respiratory syndrome virus with additional 120aa deletion in Nsp2 region in Jiangxi, China. ⁶²	Yu LX...Zhou YJ	30024111	2018
37	[Diagnosis and treatment of intra-abdominal infection complicated with hypothyroidism]. ⁶²	Han G...Ma Z	30588585	2018
38	Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis. ⁶²	Paolino G...Donati P	30064604	2017
39	Social support and breast cancer: A comparatory study of breast cancer survivors, women with mental depression, women with hypertension and healthy female controls. ⁶²	Salakari M...Suominen S	28667868	2017
40	Dimorphic anemia and mental depression as a result of systemic manifestations of generalized aggressive periodontitis: A pioneer case report. ⁶²	Mahajan A...Rasila D	29491590	2017
41	[Psoriasis and erectile dysfunction: An update]. ⁶²	Wu BC...Jiang R	28965388	2016
42	Client satisfaction: correlates and implications for improving HIV/AIDS treatment and care services in southern Ethiopia. ⁶²	Yakob B...Purity Ncama B	27008895	2016
43	Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice. ⁶²	Wang DD...Qi JS	27338163	2016
44	Fecal microbiota transplantation for recurrent Clostridium difficile infection: The patient experience. ⁶²	Pakyz AL...Edmond MB	26944009	2016
45	Support for the hypothesis that sexual breast stimulation is an ancestral practice and a key to understanding women's health. ⁶²	Robinson VC	26386486	2015
46	Correlates of Mental Depression Among Female Sex Workers in Southern India. ⁶²	Patel SK...Prabhakar P	26307144	2015
47	Evaluation of the antidepressant activity of Moringa oleifera alone and in combination with fluoxetine. ⁶²	Kaur G...Buttar HS	26834427	2015
48	Optimizing the compatibility of paired-herb in an ancient Chinese herbal decoction Kai-Xin-San in activating neurofilament expression in cultured PC12 cells. ⁶²	Yan L...Tsim KW	25560671	2015
49	Monetizing illness: the influence of disability assistance priming on how we evaluate the health symptoms of others. ⁶²	O'Brien RL	25577289	2015
50	Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study). ⁶²	Zhang X...Ancelin ML	25826111	2015

Sources

Genes for Mental Depression

Genes related to Mental Depression (1 elite genes):

(show top 50) (show all 61)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NOTCH3	Notch Receptor 3	Protein Coding	428.3	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	32581362
2	TWNK	Twinkle MtDNA Helicase	Protein Coding	25	Likely pathogenic ⁵
3	DCTN1	Dynactin Subunit 1	Protein Coding	10.92	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
4	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	9.23	DISEASES inferred ¹⁴
5	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	9.16	DISEASES inferred ¹⁴
6	PRODH	Proline Dehydrogenase 1	Protein Coding	8.84	DISEASES inferred ¹⁴ ¹⁴
7	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	8.76	DISEASES inferred ¹⁴
8	MIR132	MicroRNA 132	RNA Gene	8.63	DISEASES inferred ¹⁴ ¹⁴
9	H2AC18	H2A Clustered Histone 18	Protein Coding	8.5	DISEASES inferred ¹⁴ ¹⁴
10	MIR124-1	MicroRNA 124-1	RNA Gene	8.49	DISEASES inferred ¹⁴ ¹⁴
11	MIR425	MicroRNA 425	RNA Gene	8.49	DISEASES inferred ¹⁴ ¹⁴
12	CRH	Corticotropin Releasing Hormone	Protein Coding	8.32	DISEASES inferred ¹⁴
13	MIRLET7D	MicroRNA Let-7d	RNA Gene	8.31	DISEASES inferred ¹⁴ ¹⁴
14	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	8.24	DISEASES inferred ¹⁴
15	MAOA	Monoamine Oxidase A	Protein Coding	8.09	DISEASES inferred ¹⁴
16	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	8.08	DISEASES inferred ¹⁴
17	SERPINA3	Serpin Family A Member 3	Protein Coding	8.07	DISEASES inferred ¹⁴ ¹⁴
18	MIR598	MicroRNA 598	RNA Gene	7.96	DISEASES inferred ¹⁴ ¹⁴
19	IL6	Interleukin 6	Protein Coding	7.86	DISEASES inferred ¹⁴
20	POMC	Proopiomelanocortin	Protein Coding	7.82	DISEASES inferred ¹⁴
21	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	7.8	DISEASES inferred ¹⁴
22	FKBP5	FKBP Prolyl Isomerase 5	Protein Coding	7.7	DISEASES inferred ¹⁴
23	COMT	Catechol-O-Methyltransferase	Protein Coding	7.69	DISEASES inferred ¹⁴
24	MIR9-1	MicroRNA 9-1	RNA Gene	7.55	DISEASES inferred ¹⁴ ¹⁴
25	MIR144	MicroRNA 144	RNA Gene	7.54	DISEASES inferred ¹⁴ ¹⁴
26	CRHR1	Corticotropin Releasing Hormone Receptor 1	Protein Coding	7.54	DISEASES inferred ¹⁴
27	IL1B	Interleukin 1 Beta	Protein Coding	7.5	DISEASES inferred ¹⁴
28	CRP	C-Reactive Protein	Protein Coding	7.45	DISEASES inferred ¹⁴
29	DISC1	DISC1 Scaffold Protein	Protein Coding	7.43	DISEASES inferred ¹⁴
30	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	7.42	DISEASES inferred ¹⁴
31	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	7.38	DISEASES inferred ¹⁴
32	TPH2	Tryptophan Hydroxylase 2	Protein Coding	7.38	DISEASES inferred ¹⁴
33	NTRK2	Neurotrophic Receptor Tyrosine Kinase 2	Protein Coding	7.38	DISEASES inferred ¹⁴
34	HTR1B	5-Hydroxytryptamine Receptor 1B	Protein Coding	7.37	DISEASES inferred ¹⁴
35	TNF	Tumor Necrosis Factor	Protein Coding	7.35	DISEASES inferred ¹⁴
36	TPH1	Tryptophan Hydroxylase 1	Protein Coding	7.34	DISEASES inferred ¹⁴
37	MIR24-1	MicroRNA 24-1	RNA Gene	7.34	DISEASES inferred ¹⁴ ¹⁴
38	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	7.34	DISEASES inferred ¹⁴
39	DRD2	Dopamine Receptor D2	Protein Coding	7.32	DISEASES inferred ¹⁴
40	SLC6A2	Solute Carrier Family 6 Member 2	Protein Coding	7.28	DISEASES inferred ¹⁴
41	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	7.27	DISEASES inferred ¹⁴
42	MIR128-1	MicroRNA 128-1	RNA Gene	7.26	DISEASES inferred ¹⁴ ¹⁴
43	GRIN2B	Glutamate Ionotropic Receptor NMDA Type Subunit 2B	Protein Coding	7.25	DISEASES inferred ¹⁴
44	OXTR	Oxytocin Receptor	Protein Coding	7.22	DISEASES inferred ¹⁴
45	CACNA1C	Calcium Voltage-Gated Channel Subunit Alpha1 C	Protein Coding	7.21	DISEASES inferred ¹⁴
46	GRIA1	Glutamate Ionotropic Receptor AMPA Type Subunit 1	Protein Coding	7.16	DISEASES inferred ¹⁴
47	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.11	DISEASES inferred ¹⁴ ¹⁴
48	OPN4	Opsin 4	Protein Coding	7.09	DISEASES inferred ¹⁴
49	LHB	Luteinizing Hormone Subunit Beta	Protein Coding	6.98	DISEASES inferred ¹⁴
50	GRM2	Glutamate Metabotropic Receptor 2	Protein Coding	6.98	DISEASES inferred ¹⁴

Sources

Variations for Mental Depression

ClinVar genetic disease variations for Mental Depression:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	OGDHL	NM_018245.3(OGDHL):c.2174A>T (p.Asn725Ile)	SNV	Affects	1292053		GRCh37: 10:50947852-50947852 GRCh38: 10:49739806-49739806
2	NOTCH3	NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg)	SNV	Pathogenic	812745	rs1555729455	GRCh37: 19:15302816-15302816 GRCh38: 19:15192005-15192005
3	TWNK	NM_021830.5(TWNK):c.1121G>A (p.Arg374Gln)	SNV	Likely Pathogenic	426106	rs1554887097	GRCh37: 10:102749088-102749088 GRCh38: 10:100989331-100989331
4	NOTCH3	NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser)	SNV	Likely Pathogenic	812744	rs1599391986	GRCh37: 19:15300140-15300140 GRCh38: 19:15189329-15189329
5	MRE11	NM_005591.4(MRE11):c.229G>A (p.Glu77Lys)	SNV	Uncertain Significance	481777	rs779269083	GRCh37: 11:94219175-94219175 GRCh38: 11:94486009-94486009
6	MRE11	NM_005591.4(MRE11):c.1727G>A (p.Arg576Gln)	SNV	Uncertain Significance	127974	rs139461096	GRCh37: 11:94180441-94180441 GRCh38: 11:94447275-94447275

Sources

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Sources

Pathways for Mental Depression

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.47	POMC OXT NOTCH3 IL6 HTR2A HTR1A
2	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.64	POMC MAOA IL6
3	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.3	SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
4	Prader-Willi and Angelman syndrome ⁷⁴	11.28	POMC OXT BDNF
5	Serotonin and anxiety ⁷⁴ Show member pathways Serotonin and anxiety-related events ⁷⁴	10.92	POMC HTR2A HTR1A CRH
6	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.79	SLC6A4 MAOA HTR1A
7	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶⁰	10.7	SLC6A4 MAOA HTR2A HTR1A
8	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶⁰	10.21	POMC CRH

Sources

GO Terms for Mental Depression

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	serotonin receptor signaling pathway	GO:0007210	9.46	HTR2A HTR1A
2	behavior	GO:0007610	9.26	HTR2A HTR1A
3	sperm ejaculation	GO:0042713	9.26	SLC6A4 OXT
4	memory	GO:0007613	9.23	SLC6A4 OXT HTR2A BDNF